A novel class of inhibitors that disrupts the stability of integrin heterodimers identified by CRISPR-tiling-instructed genetic screens

通过 CRISPR 基因编辑指导的基因筛选,发现了一类能够破坏整合素异二聚体稳定性的新型抑制剂。

阅读:1
作者:Nicole M Mattson ,Anthony K N Chan ,Kazuya Miyashita ,Elizaveta Mukhaleva ,Wen-Han Chang ,Lu Yang ,Ning Ma ,Yingyu Wang ,Sheela Pangeni Pokharel ,Mingli Li ,Qiao Liu ,Xiaobao Xu ,Renee Chen ,Priyanka Singh ,Leisi Zhang ,Zeinab Elsayed ,Bryan Chen ,Denise Keen ,Patrick Pirrotte ,Steven T Rosen ,Jianjun Chen ,Mark A LaBarge ,John E Shively ,Nagarajan Vaidehi ,Russell C Rockne ,Mingye Feng ,Chun-Wei Chen

Abstract

The plasma membrane is enriched for receptors and signaling proteins that are accessible from the extracellular space for pharmacological intervention. Here we conducted a series of CRISPR screens using human cell surface proteome and integrin family libraries in multiple cancer models. Our results identified ITGAV (integrin αV) and its heterodimer partner ITGB5 (integrin β5) as the essential integrin α/β pair for cancer cell expansion. High-density CRISPR gene tiling further pinpointed the integral pocket within the β-propeller domain of ITGAV for integrin αVβ5 dimerization. Combined with in silico compound docking, we developed a CRISPR-Tiling-Instructed Computer-Aided (CRISPR-TICA) pipeline for drug discovery and identified Cpd_AV2 as a lead inhibitor targeting the β-propeller central pocket of ITGAV. Cpd_AV2 treatment led to rapid uncoupling of integrin αVβ5 and cellular apoptosis, providing a unique class of therapeutic action that eliminates the integrin signaling via heterodimer dissociation. We also foresee the CRISPR-TICA approach to be an accessible method for future drug discovery studies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。